KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer
Status:
Not yet recruiting
Trial end date:
2028-12-31
Target enrollment:
Participant gender:
Summary
This is a phase I clinical trial to determine the maximum tolerated dose (MTD) of KK-LC-1
TCR-T cells for the treatment of metastatic cancers that express KK-LC-1. Participants will
receive a conditioning regimen, KK-LC-1 TCR-T cells, and aldesleukin. The safety profile and
clinical response to treatment will be determined.
Phase:
Phase 1
Details
Lead Sponsor:
Christian Hinrichs
Collaborators:
Cancer Immunology and Metabolism Center of Excellence at Rutgers Cancer Institute of New Jersey National Cancer Institute (NCI) T Cure Bioscience